Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
25 Oct 2024
25 Oct 2024
Historique:
received:
23
08
2024
accepted:
11
10
2024
revised:
07
10
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
25
10
2024
Statut:
epublish
Résumé
This viewpoint summarizes findings from analyses of large personal patient databases of myeloproliferative neoplasms (MPNs) to assess the impact of thrombosis on mortality, disease progression, and second cancers (SC). Despite advances, the current incidence of arterial and venous thrombosis remains a challenge. These events appear to signal a more aggressive disease course, as evidenced by their association with myelofibrosis progression and mortality using multistate models and time-dependent multivariable analysis. Inflammatory biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR), are associated with the aggressiveness of polycythemia vera (PV) and essential thrombocythemia (ET), linking thrombosis to SC risk. This suggests a common inflammatory pathway likely influencing cardiovascular disease and cancer incidence. Notably, this is observed more frequently in younger patients, likely due to prolonged exposure to MPN and environmental inflammatory triggers. These data underscore the need for new studies to validate these associations, delineate the sequence of events, and identify therapeutic targets to mitigate thrombotic events and potentially improve overall patient outcomes in MPN.
Identifiants
pubmed: 39455571
doi: 10.1038/s41408-024-01169-6
pii: 10.1038/s41408-024-01169-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
188Informations de copyright
© 2024. The Author(s).
Références
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28.
pubmed: 35767897
pmcid: 9479031
doi: 10.1182/blood.2022015850
Rungjirajittranon T, Owattanapanich W, Ungprasert P, Siritanaratkul N, Ruchutrakool T. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer. 2019;19:184.
pubmed: 30819138
pmcid: 6393965
doi: 10.1186/s12885-019-5387-9
Barbui T, Carobbio A, De Stefano V. Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment. Res Pr Thromb Haemost. 2022;6:e12657.
doi: 10.1002/rth2.12657
Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22:437–8.
pubmed: 17728787
doi: 10.1038/sj.leu.2404914
Tefferi A, Alkhateeb H, Gangat N. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm. Blood Cancer J. 2023;13:108.
pubmed: 37460550
pmcid: 10352315
doi: 10.1038/s41408-023-00878-8
Loscocco GG, Gesullo F, Capecchi G, Atanasio A, Maccari C, Mannelli F, et al. One thousand patients with essential thrombocythemia: the Florence-CRIMM experience. Blood Cancer J. 2024;14:10.
pubmed: 38238287
pmcid: 10796728
doi: 10.1038/s41408-023-00968-7
Guglielmelli P, Loscocco GG, Mannarelli C, Rossi E, Mannelli F, Ramundo F, et al. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J. 2021;11:199.
pubmed: 34897288
pmcid: 8665926
doi: 10.1038/s41408-021-00581-6
Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–69.
pubmed: 29515238
pmcid: 5986069
doi: 10.1038/s41375-018-0077-1
Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, et al. In: Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler C (eds). Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:1033–62.
Carobbio A, Vannucchi AM, Rumi E, De Stefano V, Rambaldi A, Carli G, et al. Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach. Blood Cancer J. 2023;13:115.
pubmed: 37507408
pmcid: 10382585
doi: 10.1038/s41408-023-00887-7
Barbui T, Carobbio A, Thiele J, Gangat N, Rumi E, Rambaldi A, et al. The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1545 patients. Blood Cancer J. 2023;13:187.
pubmed: 38102114
pmcid: 10724164
doi: 10.1038/s41408-023-00960-1
Pemmaraju N, Gerds AT, Yu J, Parasuraman S, Shah A, Xi A, et al. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia. Leuk Res. 2022;115:e106809.
doi: 10.1016/j.leukres.2022.106809
Barbui T, Carobbio A. Prediction models for essential thrombocythemia from two longitudinal studies involving 2000 patients. Blood Cancer J. 2024;14:17.
pubmed: 38253717
pmcid: 10803320
doi: 10.1038/s41408-024-00987-y
De Stefano V, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, et al. Arterial thrombosis in philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. Blood. 2020;135:381–6.
pubmed: 31869407
doi: 10.1182/blood.2019002614
Ghirardi A, Carobbio A, Guglielmelli P, Rambaldi A, Stefano V, Vannucchi AM, et al. Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study. Blood Cancer J. 2024;14:68.
pubmed: 38649342
pmcid: 11035557
doi: 10.1038/s41408-024-01052-4
Hultcrantz M, Björkholm M, Dickman PW, Landgren O, Derolf ÅR, Kristinsson SY, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018;168:317–25.
pubmed: 29335713
pmcid: 7533681
doi: 10.7326/M17-0028
Barbui T, Vannucchi AM, Finazzi G, Finazzi MC, Masciulli A, Carobbio A, et al. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study. Am J Hematol. 2017;92:1131–6.
pubmed: 28699191
doi: 10.1002/ajh.24851
Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N. Engl J Med. 1995;332:1132–6.
pubmed: 7700286
doi: 10.1056/NEJM199504273321704
Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl J Med. 2005;353:33–45.
pubmed: 16000354
doi: 10.1056/NEJMoa043800
Barbui T, Stefano V, Ghirardi A, Masciulli A, Finazzi G, Vannucchi AM. Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera. Blood Cancer J. 2018;8:124.
pubmed: 30478311
pmcid: 6255832
doi: 10.1038/s41408-018-0161-9
Ferrari A, Carobbio A, Masciulli A, Ghirardi A, Finazzi G, De Stefano V, et al. Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. Haematologica. 2019;104:2391–9.
pubmed: 31123026
pmcid: 6959178
doi: 10.3324/haematol.2019.221234
Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. 2014;124:3021–3.
pubmed: 25377561
doi: 10.1182/blood-2014-07-591610
Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224–32.
pubmed: 15710945
doi: 10.1200/JCO.2005.07.062
Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874–81.
pubmed: 23739289
pmcid: 3768558
doi: 10.1038/leu.2013.163
Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N. Engl J Med. 2013;368:22–33.
pubmed: 23216616
doi: 10.1056/NEJMoa1208500
Liu A, Naymagon L, Tremblay D. Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment considerations and unmet needs. Cancers. 2022;15:11.
pubmed: 36612008
pmcid: 9817858
doi: 10.3390/cancers15010011
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
pubmed: 27069254
doi: 10.1182/blood-2016-03-643544
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19.
pubmed: 35732831
pmcid: 9252913
doi: 10.1038/s41375-022-01613-1
Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179–84.
pubmed: 21747083
doi: 10.1200/JCO.2010.34.5298
Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115:778–82.
pubmed: 19965680
doi: 10.1182/blood-2009-08-238956
Saliba W, Mishchenko E, Cohen S, Rennert G, Preis M. Association between myelofibrosis and thromboembolism: a population-based retrospective cohort study. J Thromb Haemost. 2020;18:916–25.
pubmed: 32017387
doi: 10.1111/jth.14754
Mora B, Guglielmelli P, Kuykendall A, Rumi E, Maffioli M, Palandri F, et al. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients. Leukemia. 2022;36:2453–60.
pubmed: 36042316
doi: 10.1038/s41375-022-01673-3
De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93:372–80.
pubmed: 18268279
doi: 10.3324/haematol.12053
De Stefano V, Carobbio A, Di Lazzaro V, Guglielmelli P, Iurlo A, Finazzi MC, et al. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. Blood Cancer J. 2018;8:25.
pubmed: 29535299
pmcid: 5849668
doi: 10.1038/s41408-018-0048-9
Barbui T, Vannucchi AM, Carobbio A, Rumi E, Finazzi G, Gisslinger H, et al. The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. Am J Hematol. 2017;92:E5–E6.
pubmed: 27737508
doi: 10.1002/ajh.24583
Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;20:1197–201.
doi: 10.1182/blood-2012-01-403279
Hasselbalch HC, Elvers M, Schafer AI. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. Blood. 2021;137:2152–60.
pubmed: 33649757
doi: 10.1182/blood.2020008109
Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood. 2008;112:3135–7.
pubmed: 18587010
pmcid: 2569168
doi: 10.1182/blood-2008-04-153783
Landolfi R, Gennaro L, Barbui T, Stefano V, Finazzi G, Marfisi R, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109:2446–52.
pubmed: 17105814
doi: 10.1182/blood-2006-08-042515
Carobbio A, Finazzi G, Antonioli E, Vannucchi AM, Barosi G, Ruggeri M, et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood. 2010;116:1051–5.
pubmed: 20479281
doi: 10.1182/blood-2010-03-272179
Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019;3:1729–37.
pubmed: 31175128
pmcid: 6560342
doi: 10.1182/bloodadvances.2019000211
Gerds AT, Mesa R, Burke JM, Grunwald MR, Stein BL, Squier P, et al. Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL. Blood. 2024;143:1646–55.
pubmed: 38142448
doi: 10.1182/blood.2023020232
Ronner L, Mascarenhas J, Moshier EL. Response to meta-analysis of leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera. Blood Adv. 2019;3:3010–2.
pubmed: 31648311
pmcid: 6849951
doi: 10.1182/bloodadvances.2019000822
Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood. 2009;114:759–63.
pubmed: 19372254
pmcid: 2716019
doi: 10.1182/blood-2009-02-206797
Wolach O, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018;10:eaan8292.
pubmed: 29643232
pmcid: 6442466
doi: 10.1126/scitranslmed.aan8292
Schuhmann MK, Kraft P, Stoll G, Lorenz K, Meuth SG, Wiendl H, et al. CD28 superagonist-mediated boost of regulatory T cells increases thrombo-inflammation and ischemic neurodegeneration during the acute phase of experimental stroke. J Cereb Blood Flow Metab J Int Soc Cereb Blood Flow Metab. 2015;35:6–10.
doi: 10.1038/jcbfm.2014.175
Steensma DP. Clinical consequences of clonal hematopoiesis of indeterminate potential. Blood Adv. 2018;2:3404–10.
pubmed: 30482770
pmcid: 6258914
doi: 10.1182/bloodadvances.2018020222
Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317–25.
pubmed: 21593864
doi: 10.1038/nature10146
Hammerschmidt DE, Bagge U, Matrai A, Dormandy JA, Ernst E. Leukocytes and the risk of ischemic diseases. JAMA. 1987;257:3553628
Sabatine MS, Morrow DA, Cannon CP, Murphy SA, Demopoulos LA, DiBattiste PM, et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (treat angina with aggrastat and determine cost of therapy with an invasive or conservative strategy- thrombolysis in myocardial infarction 18 trial) substudy. J Am Coll Cardiol. 2002;40:1761–8.
pubmed: 12446059
doi: 10.1016/S0735-1097(02)02484-1
Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, et al. Myocardial infarction accelerates atherosclerosis. Nature. 2012;487:325–9.
pubmed: 22763456
pmcid: 3401326
doi: 10.1038/nature11260
Mereweather LJ, Constantinescu-Bercu A, Crawley JTB, Salles-Crawley I. Platelet-neutrophil crosstalk in thrombosis. Int J Mol Sci. 2023;24:1266.
pubmed: 36674781
pmcid: 9861587
doi: 10.3390/ijms24021266
Döring Y, Soehnlein O, Weber C. Neutrophil extracellular traps in atherosclerosis and atherothrombosis. Circ Res. 2017;120:736–43.
pubmed: 28209798
doi: 10.1161/CIRCRESAHA.116.309692
Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol. 2021;18:666–82.
pubmed: 33958774
pmcid: 8100938
doi: 10.1038/s41569-021-00552-1
Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2011;96:315–8.
pubmed: 21173097
doi: 10.3324/haematol.2010.031070
Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, et al. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol J Hematol Oncol. 2017;10:54.
pubmed: 28228104
doi: 10.1186/s13045-017-0425-z
Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29:1356–63.
pubmed: 21300928
doi: 10.1200/JCO.2010.32.9490
Barbui T, Carobbio A, Finazzi G, Guglielmelli P, Salmoiraghi S, Rosti V, et al. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia. 2013;27:2084–6.
pubmed: 23828261
doi: 10.1038/leu.2013.207
Barosi G, Massa M, Campanelli R, Fois G, Catarsi P, Viarengo G, et al. Primary myelofibrosis: older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. Leuk Res. 2017;60:18–23.
pubmed: 28622624
doi: 10.1016/j.leukres.2017.06.004
Barosi G, Campanelli R, Catarsi P, Amici M, Abbà C, Viarengo G, et al. Plasma sIL-2Rα levels are associated with disease progression in myelofibrosis with JAK2V617F but not CALR mutation. Leuk Res. 2020;90:106319.
pubmed: 32081398
doi: 10.1016/j.leukres.2020.106319
Campanelli R, Massa M, Rosti V, Barosi G. New markers of disease progression in myelofibrosis. Cancers. 2021;13:5324.
pubmed: 34771488
pmcid: 8582535
doi: 10.3390/cancers13215324
Tefferi A, Loscocco GG, Farrukh F, Szuber N, Mannelli F, Pardanani A, et al. A globally applicable ‘triple A’ risk model for essential thrombocythemia based on age, absolute neutrophil count, and absolute lymphocyte count. Am J Hematol. 2023;98:1829–37.
pubmed: 37665758
doi: 10.1002/ajh.27079
Warny M, Helby J, Nordestgaard BG, Birgens H, Bojesen SE. Incidental lymphopenia and mortality: a prospective cohort study. CMAJ. 2020;192:E25–E33.
pubmed: 31932337
pmcid: 6957322
doi: 10.1503/cmaj.191024
Larsen MK, Skov V, Kjær L, Eickhardt-Dalbøge CS, Knudsen TA, Kristiansen MH, et al. Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study. Blood Cancer J. 2024;14:28.
pubmed: 38331919
pmcid: 10853217
doi: 10.1038/s41408-024-00994-z
Adamstein NH, MacFadyen JG, Rose LM, Glynn RJ, Dey AK, Libby P, et al. The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. Eur Heart J. 2021;42:896–903.
pubmed: 33417682
pmcid: 7936519
doi: 10.1093/eurheartj/ehaa1034
Song M, Graubard BI, Rabkin CS, Engels EA. Neutrophil-to-lymphocyte ratio and mortality in the United States general population. Sci Rep. 2021;11:464.
pubmed: 33431958
pmcid: 7801737
doi: 10.1038/s41598-020-79431-7
Carobbio A, Vannucchi AM, De Stefano V, Masciulli A, Guglielmelli P, Loscocco GG, et al. Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. Blood Cancer J. 2022;12:28.
pubmed: 35145055
pmcid: 8831521
doi: 10.1038/s41408-022-00625-5
Laganà A, Passucci M, Pepe S, Scalzulli E, Carmosino I, Costa A, et al. Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation. Eur J Haematol. 2024;112:938–43.
pubmed: 38332702
doi: 10.1111/ejh.14188
Nathan DI, Dougherty M, Bhatta M, Mascarenhas J, Marcellino BK. Clonal hematopoiesis and inflammation: a review of mechanisms and clinical implications. Crit Rev Oncol Hematol. 2023;192:104187.
pubmed: 37879493
doi: 10.1016/j.critrevonc.2023.104187
Weeks LD, Ebert BL. Causes and consequences of clonal hematopoiesis. Blood. 2023;142:2235–46.
pubmed: 37931207
doi: 10.1182/blood.2023022222
Calvillo-Argüelles O, Jaiswal S, Shlush LI, Moslehi JJ, Schimmer A, Barac A, et al. Connections between clonal hematopoiesis, cardiovascular disease, and cancer: a review. JAMA Cardiol. 2019;4:380–7.
pubmed: 30865214
doi: 10.1001/jamacardio.2019.0302
Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, et al. Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer. JACC rev top week. J Am Coll Cardiol. 2019;74:567–77.
pubmed: 31345432
pmcid: 6681657
doi: 10.1016/j.jacc.2019.06.007
Hasselbalch HC. The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev. 2013;24:133–45.
pubmed: 23415024
doi: 10.1016/j.cytogfr.2013.01.004
Hasselbalch HC, Kristiansen MH, Kjær L, Skov V, Larsen MK, Ellervik C, et al. CHIP-JAK2V617F, chronic inflammation, abnormal megakaryocyte morphology, organ failure, and multimorbidties. Blood Adv. 2024;8:681–2.
pubmed: 38134296
doi: 10.1182/bloodadvances.2023012190
De Stefano V. Arterial thrombosis and cancer: the neglected side of the coin of Trousseau syndrome. Haematologica. 2018;103:1419–21.
pubmed: 30171017
pmcid: 6119149
doi: 10.3324/haematol.2018.197814
Wilcox NS, Amit U, Reibel JB, Berlin E, Howell K, Ky B. Cardiovascular disease and cancer: shared risk factors and mechanisms. Nat Rev Cardiol. 2024. https://doi.org/10.1038/s41569-024-01017-x .
Reed SC, Croessmann S, Park BH. CHIP happens: clonal hematopoiesis of indeterminate potential and its relationship to solid tumors. Clin Cancer Res. 2023;29:1403–11.
pubmed: 36454121
pmcid: 10106364
doi: 10.1158/1078-0432.CCR-22-2598
Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219–25.
pubmed: 22318201
doi: 10.1182/blood-2011-11-394775
Coombs CC, Gillis NK, Tan X, Berg JS, Ball M, Balasis ME, et al. Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays. Clin Cancer Res J Am Assoc Cancer Res. 2018;24:5918–24.
doi: 10.1158/1078-0432.CCR-18-1201
Bertero E, Robusto F, Rulli E, D’Ettorre A, Bisceglia L, Staszewsky L, et al. Cancer incidence and mortality according to pre-existing heart failure in a community-based cohort. JACC Cardio Oncol. 2022;4:98–109.
doi: 10.1016/j.jaccao.2021.11.007
Brahmbhatt DH, Scolari FL, Billia F. Could clonal hematopoiesis explain the link between increased cancer mortality incidence in heart failure? JACC Cardio Oncol. 2022;4:283.
doi: 10.1016/j.jaccao.2022.02.008
Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, et al. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia. 2019;33:1996–2005.
pubmed: 31142846
doi: 10.1038/s41375-019-0487-8
De Stefano V, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, et al. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. Leukemia. 2016;30:2032–8.
pubmed: 27113812
doi: 10.1038/leu.2016.85
De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, et al. Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer J. 2016;6:e493.
pubmed: 27813534
pmcid: 5148051
doi: 10.1038/bcj.2016.103
Barbui T, Ghirardi A, Vannucchi AM, Marchetti M, De Stefano V. MPN-K authors. Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin. Leukemia. 2020;34:1208–9.
pubmed: 31700081
doi: 10.1038/s41375-019-0616-4
Elwood P, Morgan G, Watkins J, Protty M, Mason M, Adams R, et al. Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against. Br J Cancer. 2024;130:3–8.
pubmed: 38030748
doi: 10.1038/s41416-023-02506-5
Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM, Irvin WJ, et al. Aspirin vs placebo as adjuvant therapy for breast cancer: The Alliance A011502 Randomized Trial. JAMA. 2024;331:1714–21.
pubmed: 38683596
doi: 10.1001/jama.2024.4840
Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1833–42.
pubmed: 28855077
doi: 10.1016/S0140-6736(17)32247-X
Lythgoe MP, Prasad V. Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncology. Br J Cancer. 2022;127:785–7.
pubmed: 35739301
pmcid: 9427732
doi: 10.1038/s41416-022-01893-5